FIELD: medicine, in particular, pharmaceutics and pharmacotherapy, applicable for production of preparation for treatment of endogenic bronchial asthma and for treatment of patients suffering from this disease. SUBSTANCE: the preparation contains cytostatic, as cytostatic it uses Melfalan dispersed in an effective dose in the gas phase up to formation of aerosol, the effective dose of Melfalan makes up 0.01 to 0.5 mg, as well as the method for treatment of patients suffering from endogenic bronchial asthma, including introduction of cytostatic - Melfalan in a daily dose of 0.01 to 0.5 mg that is introduced to patients by means of inhalation. EFFECT: improved clinical results against the background of absence of by-effect of medicaments. 6 cl
Title | Year | Author | Number |
---|---|---|---|
TREATMENT OF PATIENTS SUFFERING FROM BRONCHIAL ASTHMA | 2008 |
|
RU2356544C1 |
TREATMENT OF PATIENTS SUFFERING FROM BRONCHIAL ASTHMA | 2008 |
|
RU2356574C1 |
METHOD OF TREATMENT OF STEROID-DEPENDENT BRONCHIAL ASTHMA | 2007 |
|
RU2348431C1 |
METHOD OF TREATMENT OF BRONCHIAL ASTHMA | 2017 |
|
RU2652752C1 |
METHOD FOR PREDICTING CARDIO-VASCULAR DISEASES | 2006 |
|
RU2310388C1 |
METHOD OF OPTIMISATION TREATMENT OF BRONCHIAL ASTHMA | 2009 |
|
RU2403073C1 |
METHOD OF BRONCHIAL ASTHMA THERAPY | 0 |
|
SU701639A1 |
METHOD OF TREATING BRONCHOPULMONARY DISEASES | 2018 |
|
RU2695366C1 |
INHALATION PHARMACEUTICAL FORM OF DIINDOLYLMETHANE FOR TREATING DISEASES OF UPPER RESPIRATORY PASSAGES | 2017 |
|
RU2665974C1 |
METHOD OF TREATMENT OF STEROID-DEPENDENT BRONCHIAL ASTHMA | 1987 |
|
RU2028083C1 |
Authors
Dates
2001-01-27—Published
2000-02-03—Filed